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Executive Summary 
 
The assessment of genotoxicity represents an important component of the safety 
assessment of all types of substances, relevant in the context of EU and international 
legislation aimed at the protection of human health. In general, the assessment of 
genotoxic hazard to humans follows a step-wise approach, beginning with a basic battery 
of in vitro tests followed in some cases by in vivo testing. Regulatory requirements, in 
particular for in vivo testing, vary depending on the type of substance under regulation and 
the region.  
 
In order to develop its own strategic plan for advancing the field and for having a 
framework for the prioritisation of in vitro test methods submitted for evaluation, the 
European Union Reference Laboratory for Alternatives to Animal Testing (EURL 
ECVAM) performed an assessment of the regulatory needs for this endpoint within pieces 
of EU legislation where the generation of genotoxicity information is a standard 
requirement. The EURL ECVAM strategy is based on the state of the science in the field 
of genotoxicity, including recent and on-going efforts. Although several in vitro tests are 
available at different stages of development and acceptance, they cannot at present be 
considered to fully replace animal tests currently used to evaluate the safety of substances. 
In light of this, EURL ECVAM proposes a pragmatic approach to improve the traditional 
genotoxicity testing paradigm that offers solutions in the short-term and medium-term and 
that draws on the considerable experience of 40 years of regulatory toxicology testing in 
this area. In the longer term, progress in mechanistic understanding and biomedical 
technologies will likely provide opportunities to consider completely new approaches and 
assessment strategies. However this will depend heavily on continued investment in 
research and development and the feasibility of translating research results into robust 
solutions fit for regulatory use.  
 
EURL ECVAM considers therefore that efforts should be directed towards the overall 
improvement of the current testing strategy for genotoxicity, which provides a means of 
avoiding or minimising the use of animals, according to the regulatory context. Several 
opportunities for improving the testing strategy have been identified which aim to: i) 
enhance the performance of the in vitro testing battery so that fewer in vivo follow-up tests 
are necessary; and ii) guide more intelligent in vivo follow-up testing to reduce and 
optimise the use of animals. The implementation of this strategic plan will rely on the 
cooperation of EURL ECVAM with other existing initiatives and coordinated 
contributions from various stakeholders.  
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Abbreviations and Glossary of Terms 
 
3Rs    Refinement, Reduction, Replacement 
BMBF   Federal Ministry for Education and Research (Germany) 
CGX   The Carcinogenicity and Genotoxicity eXperience (CGX) database 
CLP    Classification, Labelling and Packaging of Substances and Mixtures 
COM UK Committee on Mutagenicity of Chemicals in Food, Consumers Products and 
the Environment 
CTA    Cell Transformation Assay 
EC   European Commission 
EC No.  EC number, refers either to EINECS number, ELINCS number, NLP number or, 
EC Number appointed under REACH procedure 
ECHA    European Chemicals Agency 
EFSA    European Food Safety Authority 
EU   European Union 
EURL ECVAM European Union Reference Laboratory for Alternatives to Animal Testing 
GHS   Globally Harmonised System of classification and labelling of chemicals 
HET-MN   Hen's Egg Test- Micronucleus 
ICH International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
ILSI/HESI International Life Sciences Institute/Health and Environmental Sciences Institute 
ITS   Integrated Testing Strategy 
JRC   Joint Research Centre (of the European Commission) 
MLA    Mouse Lymphoma Assay 
NC3Rs   National (UK) Centre for Refinement, Reduction, Replacement  
NIHS   National Institute of Health Sciences, Japan 
OECD    Organisation for Economic Co-operation and Development 
QSAR   Quantitative Structure-Activity Relationship 
REACH   Registration, Evaluation, Authorisation and restriction of Chemicals 
SCCP    Scientific Committee on Consumer Products (European Commission) 
SCCS    Scientific Committee on Consumer Safety (European Commission) 
SHE   Syrian hamster embryonic stem cells 
TG   Test Guideline 
UDS   Unscheduled DNA Synthesis 
US FDA US Federal Drug Administration 
US NTP US National Toxicology Program 
VICH International Cooperation on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products 
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1. Introduction 
 
Genetic alterations in somatic and germ cells are associated with serious health effects, 
which in principle may occur even at low exposure levels. Mutations in somatic cells may 
cause cancer if they occur in proto-oncogenes, tumour suppressor genes and/or DNA 
damage response genes (Erickson, 2010). Accumulation of DNA damage in somatic cells 
has also been proposed to play a role in degenerative conditions such as accelerated ageing, 
immune dysfunction, and cardiovascular and neurodegenerative diseases (Hoeijmakers, 
2009; Slatter and Gennery, 2010; De Flora and Izzotti, 2007; Frank, 2010). Mutations in 
germ cells can lead to spontaneous abortions, infertility or heritable damage to the 
offspring and possibly to subsequent generations. 
 
The assessment of genotoxicity represents an important component of the safety 
assessment of all types of substances (e.g. pharmaceuticals, industrial chemicals, 
pesticides, biocides, food additives, cosmetic ingredients) relevant in the context of EU 
and international legislation aimed at the protection of human health (ICH, 2011; VICH, 
2012; EC no. 1907/2006; EC nos. 1107/2009b and 283/284-2013; EC no. 528/2012; 
EFSA, 2011; EC no 1223/2009 and SCCS'S notes of guidance, 1501/2012). The results of 
genotoxicity tests inform the cancer risk assessment process and are used for classification 
and labelling (C&L) of chemicals in the EU (the REACH regulation No 1907/2006 and 
Regulation (EC) No. 1272/2008 on the classification, labelling and packaging (CLP) of 
substances and mixtures) and across the world (UN Globally Harmonised System, GHS, 
2011). 
 
Genotoxicity testing includes the measurement of DNA primary damage that can be 
repaired and is therefore reversible, as well as the detection of stable and irreversible 
damage (i.e. gene mutations and chromosome aberrations) that are transmissible to the 
next generation when they occur in germ cells, and the perturbation in mechanisms 
involved in the preservation of the integrity of the genome. For an adequate evaluation of 
the genotoxic potential of a chemical substance, different endpoints (i.e. induction of gene 
mutation, structural and numerical chromosome alterations) have to be assessed, as each 
of these events has been implicated in carcinogenesis and heritable diseases. These 
changes may involve a single or block of base pairs, single gene or gene segment, or a 
block of genes or chromosomes. The term mutagenicity refers to changes in nucleotide 
sequence often referred to as point mutations that involve a small number of nucleotides 
such as base pair substitutions, small insertions and deletions, while the term 
clastogenicity is used for agents giving rise to structural chromosome aberrations. A 
clastogen can cause breaks in chromosomes that result in the loss or rearrangement of 
chromosome segments. Aneugenicity refers to the effects of agents that give rise to a 
change (gain or loss) in chromosome number. An adequate coverage of all endpoints can 
only be obtained by the use of multiple test systems (i.e. a testing battery), as no individual 
test system can cover all endpoints. The standard in vitro test battery comprises the Ames 
test (or bacterial reverse mutation assay), the in vitro mammalian cell chromosomal 
aberration test, the in vitro mammalian cell gene mutation test, and the in vitro mammalian 
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cell micronucleus test (see Annex I, Table 1). As a logical choice, any confirmatory in 
vivo follow-up test needs to cover the same endpoint as the one which showed positive 
results in vitro.  
 
Generally, the assessment of genotoxic hazard to humans follows a step-wise approach, 
beginning with a basic battery of in vitro tests followed in some cases by in vivo testing. 
Regulatory requirements, in particular for in vivo testing, vary depending on the type of 
chemical under regulation and the region. For cosmetic ingredients and products, in vivo 
testing is prohibited in the EU (EC no 1223/2009) while for industrial chemicals and 
biocidal products a positive result in one or more of the in vitro genotoxicity tests requires 
confirmation by appropriate follow-up in vivo testing (EC no. 1907/2006; EC no. 
528/2012). In these cases, if a substance is clearly negative in the in vitro battery it is 
considered as having no genotoxic hazard, thus no further in vivo study is needed. 
Regulatory requirements for pharmaceuticals, veterinary drugs and plant protection 
products foresee that the in vitro testing battery (irrespective of the outcome) is always 
followed by in vivo testing (ICH, 2011; VICH, 2012; EC nos. 1107/2009b and 283/284-
2013) (Figure 1). See Annex I for a detailed description of regulatory requirements. 
 
The purpose of this document is to present the EURL ECVAM strategy to improve 
genotoxicity testing for hazard identification and to either avoid or minimise the use of 
animals depending on the regulatory context. The EURL ECVAM strategy is based on the 
state of the science of genotoxicity testing and draws from recent initiatives undertaken by 
EURL ECVAM and others, including some current guidance documents from the 
European Food Safety Authority and the UK Committee on Mutagenicity of Chemicals in 
Food, Consumers Products and the Environment and the International Conference on 
Harmonization (EFSA Opinion, 2011; UK COM Guidance, 2011; ICH, 2011). An 
important aspect of this document is to propose solutions that can satisfy information 
requirements associated with EU legislation and which can also be considered by the 
Organisation for Economic Co-operation and Development (OECD) in the context of a 
globally harmonised approach for the assessment of genotoxicity. This strategic plan is 
intended to be inclusive in that its implementation will rely on the cooperation of EURL 
ECVAM with other related initiatives and the coordinated contributions from various 
stakeholders.  
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Figure 1. Summary of testing requirements and guidance documents for genotoxicity assessment 
under different pieces of EU legislation. 
 
 
 
2. In vitro genotoxicity approaches currently under evaluation  
 
A number of in vitro tests are currently used to screen substances for potential 
genotoxicity, yet, the in vitro testing battery cannot at present be considered to fully 
replace animal tests (Adler et al., 2011). Furthermore, in most sectors confirmatory testing 
still needs to be carried out in vivo in order to comply with regulatory requirements. While 
these in vitro tests have a good sensitivity, some (especially the in vitro mammalian cell 
tests) have a high rate of false positive results (Kirkland et al., 2005; 2007). False positives 
(also referred as irrelevant or misleading positives) are in vitro positive results that cannot 
be confirmed when followed-up in well-conducted in vivo genotoxicity and/or 
carcinogenicity assays. Thus these positive findings may trigger many unnecessary 
follow-up in vivo confirmatory tests or may even lead to abandoning the further 
development of promising substances.  
 
Improving existing assays through better understanding 
The high rate of misleading positive results in in vitro mammalian cell genotoxicity tests 
was addressed during an ECVAM workshop (Kirkland et al., 2007). It was recommended 
that better guidance should be developed on the likely mechanisms that lead to positive 
results but which are not relevant for humans, and on how to obtain evidence that such 
mechanisms are at play. Some of the reasons identified for false positives outcomes from 
in vitro testing were; excessive cytotoxicity, high cell passage-number, and compromised 
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p53 response pathways or DNA repair mechanisms in the cells used. For newly developed 
test methods, cell systems of human origin which are p53 and DNA repair proficient, and 
which have phase I and phase II metabolism, were considered to offer the best option to 
reduce false positive results in the future (Kirkland et al., 2007). The recommendations of 
this workshop have contributed to several international collaborative initiatives (e.g. by 
Cosmetics Europe, ILSI/HESI, EURL ECVAM, UK NC3Rs and JaCVAM) aiming to 
improve the existing genotoxicity in vitro tests and to identify and evaluate new cell 
systems with appropriate sensitivity but improved specificity (i.e. reduced false positive 
rate). For example, EURL ECVAM established a recommended list of genotoxic and non-
genotoxic chemicals for assessment of the performance of new and improved genotoxicity 
tests (Kirkland et al., 2008). This chemical list is used world-wide by test developers and 
other organisations. 
 
Currently, all OECD Test Guidelines (TG) related to genotoxicity are being revised taking 
also into account the knowledge acquired during the last decades of testing and the recent 
activities related to false positives (Parry et al., 2010; Kirkland and Fowler, 2010; Fowler 
et al., 2012a, 2012b). The recommendations made in the revised TGs both for 
experimental conditions and data interpretation will most probably enhance the quality of 
the data that will be produced. 
 
Maintaining the same endpoints but using novel biological models 
Several new in vitro assays, aiming at confirming positive results in the standard in vitro 
battery or providing additional mechanistic information are under development and 
evaluation.  
 
The micronucleus test and the comet assay in 3D human reconstructed skin models offer 
the potential for a more physiologically relevant approach especially regarding metabolic 
aspects to test dermally applied chemicals (Hu et al., 2010; Pfuhler et al., 2011). It has 
been anticipated that these features of the reconstructed skin models could improve the 
predictive value of a genotoxicity assessment compared with that of existing in vitro tests 
and, therefore, could be used  as follow-up tests in case of positive results from the 
standard in vitro genotoxicity testing battery (Maurici et al., 2005; Pfuhler et al., 2010). 
Validation studies of the micronucleus test using the human reconstructed skin models are 
coordinated and funded by Cosmetics Europe, and in the case of the 3D Skin Comet assay, 
by a joint effort between Cosmetics Europe and a German Consortium funded by BMBF 
(Aardema et al., 2010; Reus et al., 2013). These projects also address the integration of an 
exogenous metabolic activation system that may be required to improve the sensitivity of 
the assays to detect the genotoxic potential of chemicals activated through liver mediated 
metabolism, rather than through skin metabolism. 
 
Another promising system that has been proposed as a follow-up for in vitro positives is 
the hen's egg test for micronucleus induction, though it is not obviously a human-based 
system (HET-MN; Wolf et al., 2008). The HET-MN combines the use of the commonly 
accepted genetic endpoint “formation of micronuclei” with the well-characterised and 
complex model of the incubated hen's egg, which enables metabolic activation, 
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elimination and excretion of xenobiotics, including those that are mutagens or pro-
mutagens. The transferability and intra-/inter-laboratory reproducibility are currently 
being evaluated by a German consortium (Greywe et al., 2012). 
 
Assays based on cell lines and primary cells derived from transgenic rodents hold promise, 
(Berndt-Weis et al., 2009; Zwart et al., 2012). They can originate from different tissues 
and are expected to reduce assumptions related to extrapolation from in vitro to in vivo 
tests as they assess exactly the same endpoint and marker gene as the respective in vivo 
transgenic models (OECD, 2013). 
 
Methods addressing different endpoints 
The in vitro cell transformation assay (CTA) has been shown to closely model some key 
stages of the in vivo carcinogenesis process by measuring the transformation of cells 
(LeBoeuf et al., 1999). The CTA has the potential to detect both genotoxic and non-
genotoxic carcinogens. Although it is not a genotoxicity assay, the CTA may be 
considered as providing additional information to more routinely employed in vitro tests 
and may sometimes be used as a follow-up assay for confirmation of in vitro positive 
results from genotoxicity assays, typically as part of a weight of evidence assessment 
(Doktorova et al, 2012). Furthermore, data generated by the CTA can be useful where 
genotoxicity data for a certain substance class have limited predictive capacity (e.g. 
aromatic amines) (EFSA Opinion, 2011; Vanparys et al., 2012). However, the exact role 
of the CTA in regulatory toxicology is still under debate. Following the development of an 
OECD Detailed Review Paper collecting available CTA data and a EURL ECVAM 
recommendation, an OECD TG on CTA in Syrian hamster embryonic stem cells (SHE) is 
in development (OECD, Review paper, 2007; EURL-ECVAM, recommendation, 2012; 
Corvi and Vanparys, 2012; OECD draft TG on SHE CTA method). Another EURL 
ECVAM recommendation has been drafted on a short-term CTA in the BHAS 42 cell line 
(Sakai et al., 2011; EURL ECVAM recommendation, 2013). 
 
In the context of genotoxicity testing, the primary use of toxicogenomics-based tests is 
envisaged to be in providing information on mode of action as supporting evidence 
(Doktorova et al., 2012). The application of toxicogenomics to predict mode of action has 
been reviewed in depth (Ellinger-Ziegelbauer et al., 2009; Waters et al., 2010). Although 
the published in vitro and in vivo data set show appreciable variability in terms of genes 
differentially expressed, common features emerge with respect to molecular pathways. For 
instance, the DNA damage-responsive p53 pathway is extensively activated both by DNA 
reactive genotoxins in vitro and genotoxic carcinogens in vivo. Conversely, in vitro DNA 
non-reactive genotoxins and in vivo non-genotoxic carcinogens mostly induce an oxidative 
stress response, signalling and cell cycle progression genes (Doktorova et al., 2013; 
Jennings et al., 2013). These data represent a proof of concept that the gene expression 
profiles reflect the underlying mode of action quite well. However, additional studies 
should be performed to enlarge the number of chemicals tested and to fill the gaps in dose-
response and time-course relationships. 
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In the last few years several attempts have been made to develop and validate the 
induction of stress pathways/proteins as endpoints in genotoxicity assays by using high 
throughput screening approaches. Among these assays are the GreenScreen Human Cells 
Assay and its further adaptation to use metabolic activation as the Blue Screen Assay, both 
of which use a p53-competent TK6 lymphoblastoid cell line, genetically modified to 
incorporate a fusion of the green fluorescent protein or Luciferase reporter-gene and the 
GADD45 gene, a downstream target of p53 (Hastwell et al., 2006; Birrel et al., 2010; 
Billinton et al., 2010). Other assays are the high throughput screening luciferase reporter-
gene assays based on four different stress pathways (RAD51, Cystatin A p53 and Nrf2) in 
the HepG2 cell line (Westerink et al., 2010) and the DNA repair-deficient chicken DT40 
cell line that measures cytotoxicity by comparing these cells to parental DNA repair-
proficient cells (Yamamoto et al., 2011).  
 
Status of current approaches under evaluation and future prospects 
Although the in vitro methods mentioned above are indeed promising, they are not mature 
enough to replace the current regulatory assays. However they can already be used to 
better understand mechanisms, judge the relevance of the data obtained with the standard 
assays (e.g. differentiating DNA-reactive from DNA-non-reactive compounds), and to 
help predict in vivo effects when animals cannot be used. 
 
Other emerging technologies (Lynch et al., 2011) and non-classical methodologies for the 
evaluation of genotoxicity may ultimately drive the development of completely new 
integrated approaches to testing and assessment, which break away from the paradigm 
established over the past 40 years of regulatory testing. However considerable research 
and development effort supported by ample investment is still required before more 
'radical' solutions emerge which can stand up to the rigorous demands of regulatory testing. 
In the short to medium term therefore, reduction and possibly replacement of animal 
testing for genotoxicity assessment is most likely achievable through a pragmatic 
approach of using sound scientific rationale to improve the current testing paradigm, in a 
manner acceptable to both the regulatory and regulated communities. 
 
 
3. Strategic plan to avoid and reduce animal use in genotoxicity 
testing  
 
EURL ECVAM proposes that efforts should be directed towards the overall improvement 
of the current genotoxicity testing strategy for better hazard assessment with the use of no 
or fewer animals. Moreover, the intention is to demonstrate that the improved testing 
strategy is adequate to satisfy the information requirements of various EU regulations. The 
EURL ECVAM strategy involves the pursuit of two key aims, as follows;  
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Strategic Aim 1  Enhance the performance of the in vitro testing battery to reduce the 
need for in vivo follow-up tests. 
 
Strategic Aim 2   Reduce and optimise the use of animals during in vivo testing.  
 
Several opportunities for achieving these aims and improving the testing strategy have 
been identified (Figure 2), the realisation of which will have significant impact on 
regulatory testing in different industrial sectors. This includes helping the cosmetics 
industry to assess ingredients without in vivo testing, reducing the number of in vivo 
genotoxicity tests required under other legislation, and eventually reducing the need for in 
vivo carcinogenicity testing (Figure 3). Pursuing this strategy will initially require 
exploiting the current standard test methods and all available data, while in certain cases 
this may trigger further experimental investigations. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. EURL ECVAM strategic plan to avoid or minimise animal use in genotoxicity testing. 
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3.1. Strategic Aim 1:  Enhance the performance of the in vitro testing 
battery to reduce the need for in vivo follow-up tests 
 
 
Analysis of the most suitable combinations of in vitro genotoxicity tests is a key 
consideration for possible improvements of the testing strategies for genotoxicity. This 
applies both to the base set in vitro testing battery and to supplementary in vitro tests used 
to confirm the relevance of positive results in vitro.  
 
Objective 1.1. Improvement of existing in vitro tests 
In recent years many activities have been carried out in trying to understand how to reduce 
false positive results in the in vitro mammalian cell tests (Fellows et al., 2008; Parry et al., 
2010; Kirkland and Fowler, 2010; Fowler et al., 2012a, 2012b). It is now the opportune 
time to assess what has been achieved so far and what still needs to be done. 
 
Short-term goal 
 Review the state of art to identify if there are still areas for improvement of quality 
and relevance of the assays and if new questions have arisen from recent initiatives. 
 
 
Objective 1.2. Determine the optimal number of tests for the standard in vitro battery 
Recently, the EFSA Scientific Committee and the UK Committee on Mutagenicity of 
Chemicals in Food, Consumers Products, and the Environment (COM) recommended that 
the set of tests used in the current in vitro battery be as small as scientifically justifiable in 
order to reduce the number of false positives (EFSA Opinion, 2011; COM Guidance, 
2011). Based on a recent data analysis (Kirkland et al., 2011), a two-test initial step has 
been proposed which includes the Ames test (OECD TG 471) and the in vitro 
micronucleus test (OECD TG 487). As confirmed by a previous ECVAM retrospective 
validation study, the in vitro micronucleus test detects two of the endpoints (i.e. structural 
and numerical chromosome aberration; Corvi et al., 2006), thus the proposed two-test 
battery covers all three endpoints to be assessed in the standard testing battery.  
 
Medium-term goal 
 Promote the implementation of the two-test battery approach within the 
international regulatory community for different sectors through dialogue and 
round-table discussions among regulatory organisations, agencies and committees. 
 
 
Objective 1.3. Assessment of in vitro genotoxicity assays currently under optimisation and 
evaluation 
Several new in vitro test systems exist (described in section 3), which are at different 
stages of optimisation and evaluation. In particular, some of these tests are good 
candidates to follow up positive results from the standard battery of tests (e.g. 
micronucleus and comet assay in reconstructed skin models).  
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Medium-term goals 
 Finalisation of validation and peer review of the test methods currently under 
evaluation. 
 Contingent upon the outcome of validation, identify best ways to exploit those 
methods within the testing strategy. 
 
Objective 1.4. Identification of in vitro tests that provide supplementary information  
Further in vitro tests may be considered as part of follow-up testing for in vitro positive 
genotoxic results to generate supplementary information regarding mechanism (or mode) 
of action and to clarify the relevance of the positive results for humans. For example, in 
vitro tests that measure gene expression may be considered particularly useful.  
In addition, since different tissues may be the target of different types of compounds, it 
should be explored whether in vitro tests could provide reliable and sufficient information 
on local genotoxicity, rather than developing further in vivo tests. Based on the metabolic 
characterisation of these test systems and available data on kinetics, their usefulness in 
extrapolation to systemic and germ cell genotoxicity should be determined. 
 
Short-term goal 
 Identify useful mechanistic in vitro tests to help with the decision-making process.  
 
Medium-term goals 
 Mapping of circumstances in which such tests are needed and which ones should 
be applied. 
 Identify and assess in vitro tests that may be predictive of site-of-contact 
genotoxicity and characterise their metabolic capacity. 
 
 
Objective 1.5. Analysis of different patterns of in vitro results to identify possible 
categories of positive results from the Ames test that may be irrelevant or signify a low 
risk  
The Ames test conducted in bacteria is the most commonly used genotoxicity test within 
the in vitro battery as it is considered able to reveal DNA reactivity and DNA reactive 
compounds. It is used to assess almost all types of substances including impurities, low 
production volume chemicals, etc. Therefore, knowing whether in vitro positive results are 
accurate indicators of in vivo mutagenic potential or carcinogenicity is extremely 
important in determining whether follow-up in vivo tests are needed or whether substances 
should be further tested. Despite the many activities on false positive results in in vitro 
mammalian cell tests, positive results in the Ames test have not been analysed in the same 
way as for mammalian cell tests. In this context, EURL ECVAM recently held a workshop 
and initiated a project with the aim of 1) evaluating the predictivity of the Ames for in vivo 
genotoxicity and carcinogenicity when considered alone or in association with a 
mammalian cell assay for the detection of chromosome damage and/or gene mutations, 
and 2) better characterising the cases where the Ames test seems to lead to irrelevant (false 
positive) results (e.g. chemical classes, type of bacterial strains, magnitude of effects).  As 
data presented at the workshop were from different sources (ECHA dissemination 
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database, EFSA pesticides, carcinogens of the Carcinogenicity and Genotoxicity 
eXperience database (CGX), US NTP, US FDA, NTP, FDA, Japanese CSCL and ISHL, 
SCCS and other industry databases), it was recommended that a consolidated database be 
constructed. 
 
Short-term goal 
 Construct a consolidated database of Ames positive compounds with respective 
available in vitro and in vivo genotoxicity and carcinogenicity data. 
 
Medium-term goal 
 Determine if all types of Ames positive test results predict a similar level of 
genotoxic and carcinogenic hazard. 
 
Objective 1.6. Construct a consolidated genotoxicity database  
Gathering reliable information from genotoxicity testing which is spread across several 
databases is demanding and often time consuming.  
The generation of a reliable consolidated database, which would include information 
derived from different existing databases in a harmonised format will be useful for future 
analyses and further mechanistic understanding. Inconsistency (contradictory data derived 
from different sources) and poor quality of the data (i.e. data not compliant with the 
current state of the art) will be the main issues to be addressed in such an exercise.  The 
starting point for this activity will be the consolidated database of Ames positive results. 
 
Short-term goal 
 Promote a data sharing exercise for non-publicly available data. 
 
Medium-term goal 
 Construct a consolidated public database of genotoxicity data. 
 
 
Objective 1.7. Training programme in data interpretation 
Uncertainties in the interpretation of data from in vitro tests and appropriate use of weight 
of evidence arguments among inexperienced assessors may often lead to the request of 
unnecessary follow-up animal studies.  
 
Short-term goal 
 Initiate a training programme addressing in vitro data interpretation. 
 
 
Objective 1.8. QSAR as a tool to support weight-of-evidence assessments of genotoxicity 
QSAR models can be used alongside the in vitro battery to provide additional information 
in weight-of-evidence assessments of genotoxicity. Many QSAR models have been 
published in the literature for predicting in vitro genotoxicity and the most commonly 
modelled test has been the Ames test. Numerous studies have characterised the predictive 
performances of these models (e.g. Worth et al., 2010; Hilbrecht et al., 2011; Bakhytari et 
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al., 2013), including work carried out in the context of projects funded by the European 
Commission (EC), e.g. OSIRIS (http://www.ufz.de/Osiris) and ANTARES 
(http://www.antares-life.eu/), and by EFSA 
(http://www.efsa.europa.eu/en/supporting/pub/50e.htm). The applicability of some of 
these models, and their integration with other non-testing approaches such as read-across, 
is being explored within the EC-funded CALEIDOS project (http://www.caleidos-life.eu). 
 
In contrast to in vitro genotoxicity, relatively few QSAR models have been developed to 
predict in vivo genotoxicity. A decision tree based on structural alerts for the in vivo 
micronucleus test (Benigni et al, 2010) has been implemented in the freely available 
software tools, Toxtree and the OECD Toolbox. In addition, a commercially available tool, 
TIMES, explicitly takes metabolic pathways into account (Mekenyan et al., 2012). To 
support further QSAR development, a database of in vivo micronucleus data has been 
developed and made publicly available (Benigni et al., 2012).  
 
Short-term goal 
 Evaluate the status of QSAR methods for in vivo genotoxicity prediction, and 
identify opportunities for further model development. 
 
Medium-term goal 
 Explore the integrated use of QSAR models and in vitro tests in genotoxicity 
assessment. 
 
 
3.2. Strategic Aim 2: Reduce and optimise the use of animals during in 
vivo testing 
 
Since in vivo genotoxicity tests are still required to confirm positive in vitro results in most 
regulatory contexts, it is important to reduce and optimise the use of animals during in 
vivo follow-up tests and so avoid performing unnecessary animal tests as far as possible.  
 
 
Objective 2.1. Achieve best use of in vivo tests avoiding redundant testing 
The selection of the appropriate follow-up test is particularly important in view of the 
adoption of new in vivo genotoxicity OECD TGs (OECD TG 488 on transgenic mice and 
draft OECD TG on in vivo comet assay). New in vivo tests have been developed in order 
1) to be able to evaluate genotoxicity in almost all tissues, and 2) to measure end-points 
other than chromosome damage. However, with an increased number of in vivo tests 
available, there is a risk that more animals could be used in the future for the assessment 
of genotoxicity. The choice of the in vivo follow-up test needs to cover the same endpoint 
as the one which showed positive results in vitro. With the objective of reducing the use of 
experimental animals according to the 3Rs principles, as a default only one in vivo test 
should be performed initially. It is recommended that this test covers different endpoints in 
order to attain maximum data using the minimum number of animals whilst ensuring that 
animal welfare is not compromised further. A second in vivo test should only be 
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considered if the first in vivo test is negative, but does not properly cover all in vitro 
positive genotoxic endpoints (Dearfield, 2011). For substances that are genotoxic in vivo 
the potential to affect germ cells should be investigated mainly based on toxicokinetics 
considerations. If it is reasonable to conclude that the substance can cause heritable 
genetic damage from available information, then the substance can be considered a 
somatic and germ cell mutagen and no further testing should be performed. 
 
Short-term goal 
 Develop general guidance on above issues. Work is already on-going under the 
umbrella of the OECD considerations on Animal Welfare (Mutual Acceptance of 
Data Act, 1981; OECD, Guidance Documents, nos. 19/2000 and 34/2005).  
 
Medium-term goal 
 Develop clear guidance on the most appropriate choice of in vivo test to be used 
within a testing strategy under different scenarios, ultimately leading to better 
assessments with fewer animals.  
 
Objective 2.2. Identification of opportunities for reduction of in vivo tests 
Several opportunities for reduction were discussed during an ECVAM workshop (Pfuhler 
et al., 2009). These opportunities exist both at single test level (e.g. 1 sex versus 2 sexes, 
omission of positive control) and ITS level (e.g. integration of endpoints in the same 
animals) and need to be taken into consideration whenever possible (EFSA Opinion, 
2011). Some of these opportunities are already available and compliant from the 
regulatory point of view, but are not always implemented. Combination of different 
endpoints into a single study or incorporation of scientifically appropriate in vivo 
genotoxicity endpoints into a short-term repeated dose toxicity test (28 days) (Pfuhler et 
al., 2009; Bowen et al., 2011; Rothfuss et al., 2010, 2011; EFSA Opinion, 2011), if such a 
test is going to be performed anyhow, should always be considered. Most of the present 
genotoxicity in vivo tests (e.g. micronucleus test, comet assay, and the new Pig-a gene 
mutation assay) are amenable to such combination and integration. An integration of 
genotoxicity endpoints in the repeated dose toxicity study, when the top dose is 
appropriate (ICH S2(R1), 2011) offers the possibility for an improved interpretation of 
genotoxicity findings since such data will be evaluated in conjunction with other routine 
toxicological information obtained, such as haematology, clinical chemistry and 
histopathology also in the context of exposure (Pfuhler et al., 2009). Maximising the 
information that can be extracted from a single test (e.g. endpoint combination, analysis of 
different tissues, proof of exposure) can reduce the overall number of assays required and 
thus ultimately lead to a reduction of animals used. 
 
Short-term goals 
 Review of progress since last ECVAM workshop on reduction opportunities to 
identify further needs, especially in relation to integration of genotoxicity 
endpoints in the in vivo 28-day repeated dose toxicity test; combination of different 
genotoxicity endpoints (e.g. micronucleus and comet) in the same animal test; 
omission of positive controls. 
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 Investigate proof of exposure in the treated animals by e.g. microsampling 
techniques, such as use of dried blood spots sampling. This would avoid carrying 
out additional toxicokinetic studies. This is already under investigation by several 
organizations (e.g. NC3Rs). 
 
Objective 2.3. Formulate conditions which justify waiving of in vivo testing  
In certain cases, there may be conditions where a conscious decision not to do in vivo 
genotoxicity tests can be made. For chemicals and biocides, this may be the case on 
absence of or low exposure, knowledge about structurally similar chemicals (read-across 
and grouping) or where it can be sufficiently deduced that an in vitro positive finding is 
not relevant for in vivo situations. For pharmaceuticals, plant protection products and 
veterinary drugs where an in vivo test is always part of the standard battery, knowledge of 
the known biological effects and the modes of action of the compounds may lead to an 
estimate of the probability that the substance is a genotoxic carcinogen. 
 
Medium-term goals 
 Define conditions where positive in vitro tests are likely to not provide evidence 
for a possible genotoxicity hazard to humans. 
 Provide recommendations for the regulatory community on the criteria to omit in 
vivo genotoxicity testing. 
 Demonstrate how reliance on clear positive genotoxicity results can be used as a 
basis for classification of carcinogens in category 1B or 2, without the need to 
perform a carcinogenicity bioassay (e.g. for REACH). This needs careful 
consideration on what additional information would be necessary to come to such 
conclusions. 
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4. Evaluation of test methods submitted to EURL ECVAM 
 
EURL ECVAM will continue evaluating submitted in vitro test methods in the light of this 
strategic plan. Such evaluations typically conclude on the status of a method with regard 
to its reliability and relevance, based on the information available, and advise on whether 
it should be considered for validation and/or peer-review and perhaps submission to the 
OECD as the basis for Test Guideline development (see for further information: 
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam). In light of this EURL ECVAM strategy 
therefore, the assessment of incoming methods will be based both on their own merits and 
on the value of information they provide with respect to the methods currently in use, and 
to the gaps that have been identified in the current testing strategy. In addition, new 
methods that provide equivalent information to existing methods will also be considered in 
terms of possible advantages related to ease of use, cost, throughput and widespread 
availability. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Possible impact on regulatory testing in different sectors upon realization of the strategy 
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Annex  
Regulatory Requirements for Genotoxicity/Mutagenicity 
 
The following sections illustrate the information requirements and guidance documents for 
genotoxicity/mutagenicity within the legislation considered for the purpose of this report 
(Figure 1). The assessment of genotoxic hazard to humans follows in general a step-wise 
approach; starting with a battery of in vitro tests followed in some cases by in vivo tests 
(see Table 1 for regulatory tests). Regulatory requirements vary depending on the type of 
substance under regulation and the region, especially for in vivo testing. Quotations from 
the original legal text and/or guidelines are reported in italics).  
 
 30 
 
Table 1. Available in vitro and in vivo methods for genotoxicity/mutagenicity.  
 
Test Method 
COUNCIL 
REGULATION 
(EC) No 
440/2008 
OECD  
Test 
Guideline 
Endpoint 
in vitro/ 
in vivo 
Bacterial reverse 
mutation test  (Ames 
test) 
B.13-14 TG 471
a
 Gene mutations In vitro 
In vitro Mammalian 
chromosome aberration 
test 
B.10 TG 473
a
 Structural aberrations In vitro 
In vitro Mammalian cell 
gene mutation test 
B.17 TG 476
a,b
 
Gene mutations and 
structural chromosome 
aberrations 
In vitro 
In vitro Mammalian cell 
micronucleus test 
B.49 TG 487
a
 
Structural and numerical 
aberrations 
In vitro 
Mammalian erythrocyte 
micronucleus test 
B.12 TG 474
a
 
Structural and numerical 
aberrations 
In vivo 
Mammalian bone 
marrow chromosome 
aberration test 
B.11 TG 475
a
 Structural aberrations In vivo 
Transgenic rodent 
somatic and germ cell 
gene mutation assays 
-- TG 488 Gene mutations In vivo 
Unscheduled DNA 
Synthesis (UDS) test 
with mammalian liver 
cells 
B.39 TG 486 DNA repair activity In vivo 
Rodent Comet assay -- Draft TG DNA damage In vivo 
Rodent Dominant Lethal 
test 
B.22 TG 478 
Germ cell mutagenicity: 
structural and numerical 
chromosome aberrations 
In vivo 
Mammalian 
Spermatogonial 
Chromosome Aberration 
test 
B.23 TG 483 
Germ cell mutagenicity: 
structural chromosome 
aberrations 
In vivo 
Mouse Heritable 
Translocation assay 
B.25 TG 485 
Germ cell mutagenicity: 
structural and numerical 
chromosome aberrations 
In vivo 
Syrian Hamster Embryo 
(SHE) cell 
transformation assay 
-- Draft TG
d
 Cell transformation In vitro 
a
Most commonly used methods in regulatory genotoxicity assessment; 
b
TG 476 is under revision and two 
distinct guidelines are in preparation: one for hprt locus mutations detection and a second for tk locus. 
c
Structural chromosome aberration can be detected in the tk test. 
d
This is not a genotoxicity test, but it is 
considered a test to assess carcinogenic potential in vitro.  
OECD TGs are available at:  
http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicals.htm 
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1. Chemicals 
 
The REACH Regulation (EC) No. 1907/2006 concerning the Registration, Evaluation, 
Authorization and Restriction of Chemicals and the CLP Regulation (EC) No. 1272/2008 
are closely interlinked to each other, since the classification of a Chemical is a mandatory 
part of the REACH registration process. 
 
 
 
 
1.1. REACH Regulation 
 
The REACH Regulation (EC) No. 1907/2006 requires all companies manufacturing or 
placing a substance on the EU market in quantities greater than one tonne per year to 
register that substance with ECHA. The deadline of REACH registration is dependent on 
the tonnage band of a substance.   
 
The first REACH deadline for registering substances manufactured or imported at 1000 
tonnes or more per year, carcinogenic, mutagenic or toxic to reproduction substances 
(CMRs) above 1 tonne per year and suspected persistent, bioaccumulative and toxic 
substances (PBTs), very persistent and very bioaccumulative substances (vPvBs) above 
100 tonnes per year was on 30 November 2010. By that deadline 4300 registration 
dossiers were successfully submitted to ECHA, including nearly 3400 phase-in substances. 
 
The REACH deadline for registering substances manufactured or imported in quantities of 
100 to 1000 tonnes per year was on 31 May 2013.  By that time, 3215 companies had 
submitted 9084 registration dossiers to ECHA, consisting of 2998 unique phase-in 
substances (http://echa.europa.eu/web/guest/reach-2013; Accessed on September 10, 
2013). 
 
Phase-in substances manufactured or imported in volumes of 1-100 tonnes per year will 
need to be registered by the 31
st
 May 2018.  
 
According to a report prepared by the former European Chemicals Bureau of the JRC it 
was estimated that a high percentage of the phase-in substances (Figure 4) would have to 
undergo further in vivo genotoxicity/mutagenicity testing (Van der Jagt et al., 2004).  
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Figure 4. Estimated percentage of the total number of phase-in substances in need 
of being tested for the different toxicological endpoints under REACH (Van der 
Jagt et al. 2004, EUR 21405 EN). 
 
 
Standard information requirements for substances manufactured or imported in quantities 
of: 
 
 Annex VII (1 tonne or more)  
Mutagenicity [par. 8.4]  
In vitro gene mutation study in bacteria.  
Further mutagenicity studies shall be considered in case of a positive result. 
 
 Annex VIII (10 tonnes or more)  
i. Mutagenicity [par. 8.4] 
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ii. In vitro cytogenicity study in mammalian cells or in vitro micronucleus study. 
[par. 8.4.2]  The study does not usually need to be conducted – if adequate data 
from an in vivo cytogenicity test are available or – the substance is known to be 
carcinogenic category 1 or 2 or mutagenic category 1, 2 or 3 (referring to GHS 
categories 1A, 1B and 2, respectively).  
 
iii. In vitro gene mutation study in mammalian cells [par. 8.4.3], if a negative 
result in Annex VII and Annex VIII. The study does not usually need to be 
conducted if adequate data from a reliable in vivo mammalian gene mutation test 
are available. Appropriate in vivo mutagenicity studies shall be considered in case 
of a positive result in any of the genotoxicity studies in Annex VII or VIII.  
 
 Annex IX (100 tonnes or more)  
 
Specific rules for adaptation from Column 1 [par. 8.4] 
 
If there is a positive result in any of the in vitro genotoxicity studies described in 
Annex VII or VIII and there are no results available from an in vivo study already, 
an appropriate in vivo somatic cell genotoxicity study shall be proposed by the 
registrant.  
 
If there is a positive result from an in vivo somatic cell study available, the 
potential for germ cell mutagenicity should be considered on the basis of all 
available data, including toxicokinetic evidence. If no clear conclusions about 
germ cell mutagenicity can be made, additional investigations shall be considered. 
 
 Annex X (1000 tonnes or more)  
Specific rules for adaptation from Column 1 [par. 8.4] 
 
If there is a positive result in any of the in vitro genotoxicity studies described in 
Annexes VII or VIII, a second in vivo somatic cell test may be necessary, 
depending on the quality and relevance of all the available data.  
If there is a positive result from an in vivo somatic cell study available, the 
potential for germ cell mutagenicity should be considered on the basis of all 
available data, including toxicokinetic evidence. If no clear conclusions about 
germ cell mutagenicity can be made, additional investigations shall be considered. 
 
 
1.2. CLP Regulation 
 
The CLP Regulation ensures that the hazards presented by chemicals are clearly 
communicated to workers and consumers in the European Union through appropriate 
hazard symbols (pictograms) and labelling phrases. The CLP Regulation entered into 
force in January 2009, and the method of classifying and labelling chemicals is based on 
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the United Nations’ Globally Harmonized System (GHS) (UN 2011), 
ST/SG/AC.10/30/Rev.4 United Nations [Chapter 3.5]. 
 
Definitions and general conditions [par. 3.5.1.] 
A mutation means a permanent change in the amount or structure of the genetic material 
in a cell. The term ‘mutation’ applies both to heritable genetic changes that may be 
manifested at the phenotypic level and to the underlying DNA modifications when known 
(including specific base pair changes and chromosomal translocations). The term 
‘mutagenic’ and ‘mutagen’ will be used for agents giving rise to an increased occurrence 
of mutations in populations of cells and/or organisms.  
The more general terms ‘genotoxic’ and ‘genotoxicity’ apply to agents or processes which 
alter the structure, information content, or segregation of DNA, including those which 
cause DNA damage by interfering with normal replication processes, or which in a non-
physiological manner (temporarily) alter its replication. Genotoxicity test results are 
usually taken as indicators for mutagenic effects. 
 
Classification criteria for substances [par. 3.5.2.] 
This hazard class is primarily concerned with substances that may cause mutations in the 
germ cells of humans that can be transmitted to the progeny. However, the results from 
mutagenicity or genotoxicity tests in vitro and in mammalian somatic and germ cells in 
vivo are also considered in classifying substances and mixtures within this hazard class. 
 
Hazard categories for germ cell mutagens [Table 3.5.1] 
Category 1: Substances known to induce heritable mutations or to be regarded as if they 
induce heritable mutations in the germ cells of humans. 
 Category 1A is based on positive evidence from human epidemiological 
studies. Substances to be regarded as if they induce heritable mutations in the 
germ cells of humans. 
 Category 1B is based on:  
– positive result(s) from in vivo heritable germ cell mutagenicity tests in 
mammals; or  
– positive result(s) from in vivo somatic cell mutagenicity tests in 
mammals, in combination with some evidence that the substance has 
potential to cause mutations to germ cells.  
It is possible to derive this supporting evidence from: 
– mutagenicity/genotoxicity tests in germ cells in vivo, or  
– by demonstrating the ability of the substance or its metabolite(s) to 
interact with the genetic material of germ cells; or  
– positive results from tests showing mutagenic effects in the germ cells 
of humans, without demonstration of transmission to progeny; for 
example, an increase in the frequency of aneuploidy in sperm cells of 
exposed people. 
 
Category 2: Substances which cause concern for humans owing to the possibility that they 
may induce heritable mutations in the germ cells of humans. 
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- positive evidence obtained from experiments in mammals and/or in some 
cases from in vitro experiments, obtained from: 
a) somatic cell mutagenicity tests in vivo, in mammals; or 
b) other in vivo somatic cell genotoxicity tests which are supported by 
positive results from in vitro mutagenicity assays. 
 
 
2. Cosmetics  
 
The Regulation (EC) No. 1223/2009 establishes rules to be complied with by any cosmetic 
product made available on the market, in order to ensure the functioning of the internal 
market and a high level of protection of human health.  From 11 July 2013, this 
Regulation has replaced the Cosmetics Directive 76/768/EEC and following Amendments 
(Directive 93/35/EEC, Directive 2003/15/EC). 
 
The Regulation also prohibits the placing on the European Union market of [Chapter V, 
Article 18, Animal testing]:  
 Products where the final formulation has been the subject of animal testing;  
 Products containing ingredients or combinations of ingredients which have been 
the subject of animal testing.  
 
Based on the recent SCCS's Notes of Guidance (SCCS/1501/12), which is currently under 
revision, three assays, for the basic level testing of cosmetic substances are recommended: 
 
1. Tests for gene mutation: 
 
i)  Bacterial Reverse Mutation Test [EC B.13/14, OECD 471] 
ii) In vitro Mammalian Cell Gene Mutation Test [EC B.17, OECD 476] 
 
2. Tests for clastogenicity and aneugenicity 
 
i) In vitro Micronucleus Test [EC B.49, OECD 487]  
or 
ii) In vitro Mammalian Chromosome Aberration Test [EC B.10, OECD 473] 
 
 In cases where negative results are seen in the conducted tests, a mutagenic 
potential is excluded.  
 Likewise, in cases where a positive result is seen in one of the tests, the compound 
has to be considered as a (in vitro/intrinsic) mutagen.  
 
 
At present no validated methods are available that allow the follow-up of positive results 
from standard in vitro assays [SCCP/1212/09].  
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3. Biocides 
 
Data requirement of the Regulation (EU) No. 528/2012 are reported as follows: 
 
 Mutagenicity  [par. 8.5] The assessment of this endpoint shall comprise the 
following consecutive steps:  
 
i. An assessment of the available in vivo genotoxicity data.  
ii. An in vitro test for gene mutations in bacteria, an in vitro cytogenicity 
test in mammalian cells and an in vitro gene mutation test in mammalian 
cells are required.  
iii. Appropriate in vivo genotoxicity studies shall be considered in case of a 
positive result in any of the in vitro genotoxicity studies. 
 
 In vivo genotoxicity study  [par. 8.6] The assessment of this endpoint shall 
comprise the following consecutive steps:  
i. If there is a positive result in any of the in vitro genotoxicity studies and 
there are no results available from an in vivo study already, an 
appropriate in vivo somatic cell genotoxicity study shall be 
proposed/conducted by the applicant.  
ii. If either of the in vitro gene mutation tests is positive, an in vivo test to 
investigate unscheduled DNA synthesis shall be conducted.  
iii. A second in vivo somatic cell test may be necessary, depending on the 
results, quality and relevance of all the available data.  
iv. If there is a positive result from an in vivo somatic cell study available, 
the potential for germ cell mutagenicity should be considered on the 
basis of all available data, including toxicokinetic evidence to 
demonstrate that the substance reached the tested organ. If no clear 
conclusions about germ cell mutagenicity can be made, additional 
investigations shall be considered. 
Additional Data Set (ADS) The study/ies do (es) not generally need to be 
conducted if:  
i. The results are negative for the three in vitro tests and if no metabolites 
of concern are formed in mammals or,  
ii. Valid in vivo micronucleus data is generated within a repeat dose study 
and the in vivo micronucleus test is the appropriate test to be conducted 
to address this information requirement. 
iii. The substance is known to be carcinogenic category 1A or 1B or 
mutagenic category 1A, 1B or 2. 
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4. Plant Protection Products 
 
The Regulation (EC) No. 1107/2009 establishes rules to be complied with by any plant 
protection product made available on the market. An active substance, safener or synergist 
shall only be approved if, on the basis of assessment of higher tier genotoxicity testing 
carried out in accordance with the data requirements for the active substances, safeners or 
synergists and other available data and information, including a review of the scientific 
literature, reviewed by the Authority, it is not or it has not to be classified, in accordance 
with the provisions of CLP Regulation (EC) No 1272/2008, as mutagen category 1A or 1B. 
 
Genotoxicity testing [par. 5.4] 
Requirements of the 2013 Update of the Regulation, (EU) No 283/2013 and (EU) No 
284/2013:  
The aim of genotoxicity testing shall be to:  
– predict genotoxic potential, 
– identify genotoxic carcinogens at an early stage, 
– elucidate the mechanism of action of some carcinogens. 
 
Appropriate dose levels, depending on the test requirements, shall be used in either in 
vitro or in vivo assays. A tiered approach shall be adopted, with selection of higher tier 
tests being dependent upon interpretation of results at each stage. 
 
Special testing requirements in relation to photomutagenicity may be indicated by the 
structure of a molecule. If the Ultraviolet/visible molar extinction/absorption coefficient of 
the active substance and its major metabolites is less than 1 000 L × mol –1 × cm –1, 
photomutagenicity testing is not required. 
 
In vitro studies [par. 5.4.1] 
The following in vitro mutagenicity tests shall be performed:  
i. bacterial assay for gene mutation (Ames test),  
ii. combined test for structural and numerical chromosome aberrations in 
mammalian cells,  
iii. test for gene mutation in mammalian cells 
 
Additional 
However, if gene mutation and clastogenicity/aneuploidy are detected in a 
battery of tests consisting of Ames and in vitro micronucleus (IVM), no 
further in vitro testing needs to be conducted.  
 
If there are indications of micronucleus formation in an in vitro 
micronucleus assay further testing with appropriate staining procedures 
shall be conducted to clarify if there is an aneugenic or clastogenic response. 
Further investigation of the aneugenic response may be considered to 
determine whether there is sufficient evidence for a threshold mechanism and 
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threshold concentration for the aneugenic response (particularly for non-
disjunction).  
 
Active substances which display highly bacteriostatic properties as 
demonstrated in a range finding test shall be tested in two different in vitro 
mammalian cell tests for gene mutation. Non performance of the Ames test 
shall be justified. 
 
For active substances bearing structural alerts that have given negative 
results in the standard test battery, additional testing may be required if the 
standard tests have not been optimised for these alerts. The choice of 
additional study or study plan modifications depends on the chemical nature, 
the known reactivity and the metabolism data on the structurally alerting 
active substance. 
 
In vivo studies in somatic cells [5.4.2] 
If all the results of the in vitro studies are negative, at least one in vivo study 
shall be done with demonstration of exposure to the test tissue (such as cell 
toxicity or toxicokinetic data), unless valid in vivo micronucleus data are 
generated within a repeat dose study and the in vivo micronucleus test is the 
appropriate test to be conducted to address this information requirement. 
A negative result in the first in vivo test in somatic cells shall provide 
sufficient reassurance for active substances that are negative in the three in 
vitro tests. 
 
Additional 
For active substances for which an equivocal or a positive test result is 
obtained in any in vitro test, the nature of additional testing needed shall be 
considered on a case-by-case basis taking into account all relevant 
information using the same endpoint as in the in vitro test. 
 
If the in vitro mammalian chromosome aberration test or the in vitro 
micronucleus test is positive for clastogenicity, an in vivo test for 
clastogenicity using somatic cells such as metaphase analysis in rodent bone 
marrow or micronucleus test in rodents shall be conducted.  
 
If the in vitro micronucleus test for numerical chromosome aberrations on 
mammalian cells is positive or the in vitro mammalian chromosome test is 
positive for numerical chromosome changes, an in vivo micronucleus test 
shall be conducted. In case of positive result in the in vivo micronucleus 
assay, appropriate staining procedure such as fluorescence in-situ 
hybridisation (FISH) shall be used to identify an aneugenic and/or 
clastogenic response. 
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If either of the in vitro gene mutation tests is positive, an in vivo test to 
investigate the induction of gene mutation shall be conducted, such as the 
Transgenic Rodent Somatic and Germ Cell Gene Mutation Assay. 
 
When conducting in vivo genotoxicity studies, only relevant exposure routes 
and methods (such as admixture to diet, drinking water, skin application, 
inhalation and gavage) shall be used. There shall be convincing evidence 
that the relevant tissue will be reached by the chosen exposure route and 
application method. Other exposure techniques (such as intraperitoneal or 
subcutaneous injection) that are likely to result in abnormal kinetics, 
distribution and metabolism shall be justified. 
Consideration shall be given to conducting an in vivo test as part of one of 
the short-term toxicity studies (described under point 5.3) 
 
In vivo studies in germ cells [par. 5.4.3] 
The necessity for conducting these tests shall be considered on a case by case 
basis, taking into account information regarding toxicokinetics, use and 
anticipated exposure. 
 
For most of the active substances recognised as in vivo somatic cell 
mutagens no further genotoxicity testing shall be necessary since they will be 
considered to be potential genotoxic carcinogens and potential germ cell 
mutagens. 
 
Additional 
However, in some specific cases germ cells studies may be undertaken to 
demonstrate whether a somatic cell mutagen is or is not a germ cell mutagen. 
 
The type of mutation should be also considered when selecting the 
appropriate test. A study for the presence of DNA adducts in gonad cells may 
also be considered. 
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5. Pharmaceuticals 
 
The standard test battery for genotoxicity consists of two equally suitable Options as 
reported in the S2 (R1) ICH Guideline [Chapter 2]:  
 
 Option 1 
i. A test for gene mutation in bacteria. 
ii. A cytogenetic test for chromosomal damage (the in vitro metaphase 
chromosome aberration test or in vitro micronucleus test), or an in vitro 
mouse lymphoma Tk gene mutation assay. 
iii. An in vivo test for genotoxicity, generally a test for chromosomal damage 
using rodent hematopoietic cells, or for micronuclei or for chromosomal 
aberrations in metaphase cells. 
 
 Option 2 
i. A test for gene mutation in bacteria. 
ii. An in vivo assessment of genotoxicity with two different tissues, usually an 
assay for micronuclei using rodent hematopoietic cells and a second in 
vivo assay. Typically this would be a DNA strand breakage assay in liver, 
unless otherwise justified. 
 
Under both standard battery options, either acute or repeat dose study designs in vivo can 
be used. In case of repeated administrations, attempts should be made to incorporate the 
genotoxicity endpoints into toxicity studies, if scientifically justified. When more than one 
endpoint is evaluated in vivo it is preferable that they are incorporated into a single study. 
Often sufficient information on the likely suitability of the doses for the repeat-dose 
toxicology study is available before the study begins and can be used to determine whether 
an acute or an integrated test will be suitable. 
 
For compounds that give negative results, the completion of either option of the standard 
test battery, performed and evaluated in accordance with current recommendations, will 
usually provide sufficient assurance of the absence of genotoxic activity and no additional 
tests are warranted. Compounds that give positive results in the standard test battery 
might, depending on their therapeutic use, need to be tested more extensively. 
 
There are several in vivo assays that can be used as the second part of the in vivo 
assessment under option 2, some of which can be integrated into repeat-dose toxicology 
studies. The liver is typically the preferred tissue because of exposure and metabolizing 
capacity, but choice of in vivo tissue and assay should be based on factors such as any 
knowledge of the potential mechanism, of the metabolism in vivo, or of the exposed tissues 
thought to be relevant.  
 
Information on numerical changes can be derived from the mammalian cell assays in vitro 
and from the micronucleus assays in vitro or in vivo. Elements of the standard protocols 
that can indicate such potential are elevations in the mitotic index, polyploidy induction 
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and micronucleus evaluation. There is also experimental evidence that spindle poisons 
can be detected in MLA. The preferred in vivo cytogenetic test under Option 2 is the 
micronucleus assay, not a chromosome aberration assay, to include more direct capability 
for detection of chromosome loss (potential for aneuploidy).  
 
The suggested standard set of tests does not imply that other genotoxicity tests are 
generally considered inadequate or inappropriate. Additional tests can be used for further 
investigation of genotoxicity test results obtained in the standard battery. Alternative 
species, including non-rodents, can also be used if indicated, and if sufficiently validated. 
 
Under conditions in which one or more tests in the standard battery cannot be employed 
for technical reasons, alternative validated tests can serve as substitutes provided 
sufficient scientific justification is given. 
 
Chapters (2-5) of the ICH S2(R1) Guideline contain also detailed information and 
modifications to the test battery and specific recommendations to the in vitro and in vivo 
studies and on evaluation of test results and on follow-up test strategies. 
 
 
 
 
6. Veterinary Drugs 
 
A battery of three tests is recommended in the VICH GL23 Guideline (October 2012, 
under revision) for use as a screen of veterinary drugs for genotoxicity [Chapter 2]: 
 
i. A test for gene mutation in bacteria. 
ii. A cytogenetic test for chromosomal damage (the in vitro metaphase 
chromosome aberration test or in vitro micronucleus test), or an in vitro 
mouse lymphoma tk gene mutation assay. 
iii. An in vivo test for chromosomal effects using rodent haematopoietic cells. 
 
Modifications can be applied and modified protocols should be used where it is evident 
that standard conditions will give a false negative result. 
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7.  Other relevant documents  
 
 
7.1 EFSA Opinion on genotoxicity testing strategies 
 
This is an EFSA Scientific Committee Review of the current state-of-the-science on 
genotoxicity testing providing a commentary and recommendations on genotoxicity 
testing strategies (EFSA, 2011). A step-wise approach is recommended for the generation 
and evaluation of data on genotoxic potential, beginning with a basic battery of in vitro 
tests, comprising a bacterial reverse mutation assay and an in vitro micronucleus assay. It 
is suggested to consider whether specific features of the test substance might require 
substitution of one or more of the recommended in vitro tests by other in vitro or in vivo 
tests in the basic battery. In the event of negative in vitro results, it can be concluded that 
the substance has no genotoxic potential. In case of inconclusive, contradictory or 
equivocal results, it may be appropriate to conduct further testing in vitro. In case of 
positive in vitro results, review of the available relevant data on the test substance and, 
where necessary, an appropriate in vivo study to assess whether the genotoxic potential 
observed in vitro is expressed in vivo is recommended. The approach to in vivo testing 
should be also step-wise. The combination of assessing different endpoints in different 
tissues in the same animal in vivo should also be considered. 
 
 
7.2 UK Committee on Mutagenicity of Chemicals in Food (COM) Guidance 
 
The COM Guidance provides a strategy for testing chemical substances where no 
genotoxicity data are available (COM, 2011). 
 
 Stage 0: Preliminary considerations prior to testing. Analysis of Physico-chemical 
and Toxicological Properties; (Q)SAR models for prediction of mutagenic activity; 
Screening tools ie. in silico approach]. 
 Stage 1: In vitro genotoxicity testing. The strategy includes using appropriate tests 
to gain an insight into the nature of the genotoxic effects of a test substance and 
also to avoid false positive results. It comprises a two-test core system (namely an 
Ames test and in vitro micronucleus test) with the objective of assessing mutagenic 
potential by investigating three different end points (gene mutation, structural 
chromosomal damage and changes in chromosome number). 
 Stage 2: In vivo genotoxicity testing.  The in vivo genotoxicity testing strategy has 
to be designed on a case-by case basis and can be used to address aspects of in vivo 
mutagenicity. 
 
7.3 Review on Alternative (non-animal) methods for cosmetics testing (Adler et al., 2011) 
 
With regard to the 7th Amendment to the EU Cosmetics Directive to prohibit animal-
tested cosmetics on the market from 2013, the European Commission invited stakeholder 
bodies (industry, non-governmental organisations, EU Member States, and the 
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Commission’s Scientific Committee on Consumer Safety) to identify scientific experts in 
five toxicological areas, i.e. toxicokinetics, repeated dose toxicity, carcinogenicity, skin 
sensitisation, and reproductive toxicity for which the Directive foresees that the 2013 
deadline could be further extended in case alternative and validated methods would not be 
available in time. The selected experts were asked to analyse the status and prospects of 
alternative methods and to provide a scientifically sound estimate of the time necessary to 
achieve full replacement of animal testing.  
 
In relation to the carcinogenicity endpoint, the experts evidenced impediments for a full 
replacement of animal testing in due time. 
 
They stated that the carcinogenic potential of a chemical substance is far to be fully 
determined and/or mimicked by the use of non-animal testing because of the complexity 
of the carcinogenesis process, the multi-stage nature of its evolution and complex 
biological interactions. The 2-year cancer bioassay in rodents is widely regarded as the 
gold standard to evaluate cancer hazard and potency; however this test is rarely done on 
cosmetics ingredients. Instead a combination of shorter-term studies has been used, 
including in vitro and in vivo genotoxicity assays to assess genotoxic potential and 
repeated-dose (typically 90-day) toxicity studies to assess the risk of non genotoxic 
chemicals. Therefore, their conclusion was that the animal testing ban under the 7
th
 
Amendment to the Cosmetics Directive will have a strong impact on the ability to evaluate 
and conduct a quantitative risk assessment for carcinogenic potential of cosmetics 
ingredients. This impact is not only due  to the ban on the cancer bioassay itself, but 
mainly to the ban of in vivo genotoxicity testing, any repeated-dose toxicity testing and 
other tests such as in vivo toxicokinetics studies and in vivo mechanistic assays. 
 
Although several in vitro short-term tests at different stages of development and 
acceptance are available, at the current status these will not be sufficient to fully replace 
the animal tests needed to confirm the safety of cosmetics ingredients. However, for some 
chemical classes, the available methods might be sufficient to rule out carcinogenic 
potential in a weight of evidence approach. Taking into consideration the state of the art of 
non-animal methods, the experts were unable to suggest a timeline for full replacement of 
animal tests currently needed to fully evaluate carcinogenic risk of chemicals.  
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Abstract 
 
The assessment of genotoxicity represents an important component of the safety assessment of all types of 
substances. Although several in vitro tests are available at different stages of development and acceptance, 
they cannot at present be considered to fully replace animal tests needed to evaluate the safety of 
substances. Based on an analysis of regulatory requirements for this endpoint within different pieces of EU 
legislation, EURL ECVAM proposes a pragmatic approach to improve the traditional genotoxicity testing 
paradigm that offers solutions in both the short- and medium-term and that draws on the considerable 
experience of 40 years of regulatory toxicology testing in this area. EURL ECVAM considers that efforts 
should be directed towards the overall improvement of the current testing strategy for better hazard and 
risk assessment approaches, which either avoids or minimises the use of animals, whilst satisfying 
regulatory information requirements, irrespective of regulatory context. Several opportunities for the 
improvement of the testing strategy have been identified which aim to i) enhance the performance of the in 
vitro testing battery so that fewer in vivo follow-up tests are necessary and ii) guide more intelligent in 
vivo follow-up testing to reduce unnecessary use of animals. The implementation of this strategic plan will 
rely on the cooperation of EURL ECVAM with other existing initiatives and the coordinated contribution from 
various stakeholders. 
       
 
 
As the Commission’s in-house science service, the Joint Research Centre’s mission is to 
provide EU policies with independent, evidence-based scientific and technical support 
throughout the whole policy cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key 
societal challenges while stimulating innovation through developing new standards, 
methods and tools, and sharing and transferring its know-how to the Member States 
and international community. 
 
Key policy areas include: environment and climate change; energy and transport; 
agriculture and food security; health and consumer protection; information society and 
digital agenda; safety and security including nuclear; all supported through a cross-
cutting and multi-disciplinary approach. 
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